Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045694 · ClinicalTrials.gov registry record · Phase 4
Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT01045694 is a Phase 4 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 8 participants.
The verdict
NCT01045694, a Phase 4 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
Basal arthritis of the thumb is a common condition with increased prevalence in post-menopausal women, obese persons, and the elderly. Surgical options are varied and efficacious, but not all patients are candidates for surgery. The successes and pitfalls of previous, similar trials are carefully considered in the creation of our own. Though steroid injection is the standard of care in basal joint arthritis, current data does not support its efficacy beyond placebo effect. No trial has yet examined the efficacy of botulinum toxin type A (BTX-A) injection into the basal thumb joint nor compared it to steroid. Since efficacy of steroid is questionable at best, our hope is that BTX-A injection of the basal joint might be the next great tool in treating this common, debilitating disease.
Interventions
- DRUG Lidocaine
- DRUG Botulinum Toxin Type A
- DRUG Steroid - Triamcinolone Acetonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01045694
The ClinicalTrials.gov registry entry for NCT01045694 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lidocaine is the first listed.
NCT01045694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01045694 about?
NCT01045694 is a clinical study titled "Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint". Basal arthritis of the thumb is a common condition with increased prevalence in post-menopausal women, obese persons, and the elderly. Surgical options are varied and efficacious, but not all patients are candidates for surgery. The successes and pitfalls of previous, similar trials are carefully co...
What is the current status of trial NCT01045694?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2011-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01045694?
The interventions under investigation include: Lidocaine (DRUG), Botulinum Toxin Type A (DRUG), Steroid - Triamcinolone Acetonide (DRUG).
Who is sponsoring clinical trial NCT01045694?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.